Maropitant: Neurokinin-1 Receptor Antagonist for Veterinary Use
Maropitant is a selective neurokinin-1 (NK1) receptor antagonist developed exclusively for veterinary medicine. It blocks the binding of substance P at NK1 receptors in the emetic center (chemoreceptor trigger zone and nucleus tractus solitarius), providing broad-spectrum antiemetic activity against both central and peripheral emetic stimuli. Maropitant is effective against motion sickness, drug-induced emesis, and visceral-origin nausea.
Product Profile
| CAS Number | 147116-67-4 |
|---|---|
| Molecular Formula | C32H40N2O |
| Appearance | White to off-white powder |
| Therapeutic Category | Veterinary antiemetic (NK1 antagonist) |
| Storage | Room temperature |
Applications
Maropitant citrate is approved for the prevention and treatment of vomiting in dogs and cats. In dogs, it is dosed at 2 mg/kg orally or 1 mg/kg subcutaneously once daily. In cats, it is approved for the prevention of vomiting at 1 mg/kg subcutaneously. Maropitant is routinely used preoperatively to prevent anesthesia-related nausea and as supportive care during chemotherapy in veterinary oncology. It also possesses visceral analgesic properties mediated through NK1 antagonism, making it a useful adjunct in multimodal pain management protocols. Available as oral tablets and injectable solution.
Why Source from TCS
TCS supplies maropitant to veterinary pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Maropitant 147116-67-4?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Maropitant 147116-67-4 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Maropitant 147116-67-4?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.